ARTICLE · 04 SEPTEMBER 2023
PTAB Issues Final Written Decisions Finding Claims Of Tocilizumab-related Patents Invalid
On August 29, 2023, the PTAB issued final written decisions in IPR2022-00578 and IPR2022-00579, filed by Celltrion on two patents related to tocilizumab — U.S. Patent Nos. 8,580,264 and 10,874,677, owned by Chugai Seiyaku Kabushiki Kaisa, Genentech, Inc, and Hoffmann La Roche, Inc.
United StatesIntellectual Property
On August 29, 2023, the PTAB issued final written decisions in
IPR2022-00578 and IPR2022-00579, filed by Celltrion on two
patents related to tocilizumab - U.S. Patent Nos. 8,580,264 and
10,874,677, owned by Chugai Seiyaku Kabushiki Kaisa, Genentech,
Inc, and Hoffmann La Roche, Inc. The '264 patent claims are
directed to methods of treating rheumatoid arthritis (RA) with a
subcutaneous fixed dose of an anti-IL-6 receptor antibody, and the
'677 patent claims are directed to a subcutaneous
administration device which contains and delivers tocilizumab. The
PTAB ruled that all challenged claims (1-12) of the '264 patent
are invalid as obvious and/or anticipated by prior art references,
and that all challenged claims (1-8) of the '677 patent are
invalid as obvious.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
View source
